Review



human aortic endothelial cells  (Cell Applications Inc)


Bioz Verified Symbol Cell Applications Inc is a verified supplier
Bioz Manufacturer Symbol Cell Applications Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Cell Applications Inc human aortic endothelial cells
    TSP‐2 inhibits angiogenesis in early passage ECs, and TSP‐5 may be protective against tubule disruption. (A, B) Angiogenesis was assessed by plating ECs overnight on a Matrigel‐based <t>endothelial</t> tubule formation assay and pretreating with or without TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in early passage ECs, but TSP‐5 inhibited tubule formation in late passage ECs. (C, D) To assess tubule disruption, EC tubules were allowed to form overnight and then treated for 24 h with TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in late passage ECs (D), TSP‐5 increased tubule formation in early passage ECs (C). In the postformation treatment groups, late passage ECs had more tubule disruption than early passage cells. Values are means ± SE. Student's t ‐test performed for analysis, * p < 0.05 compared to nontreatment.
    Human Aortic Endothelial Cells, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 94/100, based on 66 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human aortic endothelial cells/product/Cell Applications Inc
    Average 94 stars, based on 66 article reviews
    human aortic endothelial cells - by Bioz Stars, 2026-02
    94/100 stars

    Images

    1) Product Images from "Age and Sex Impact the Role of Thrombospondin‐2 and Thrombospondin‐5 in Response to Hindlimb Ischemia"

    Article Title: Age and Sex Impact the Role of Thrombospondin‐2 and Thrombospondin‐5 in Response to Hindlimb Ischemia

    Journal: FASEB BioAdvances

    doi: 10.1096/fba.2025-00258

    TSP‐2 inhibits angiogenesis in early passage ECs, and TSP‐5 may be protective against tubule disruption. (A, B) Angiogenesis was assessed by plating ECs overnight on a Matrigel‐based endothelial tubule formation assay and pretreating with or without TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in early passage ECs, but TSP‐5 inhibited tubule formation in late passage ECs. (C, D) To assess tubule disruption, EC tubules were allowed to form overnight and then treated for 24 h with TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in late passage ECs (D), TSP‐5 increased tubule formation in early passage ECs (C). In the postformation treatment groups, late passage ECs had more tubule disruption than early passage cells. Values are means ± SE. Student's t ‐test performed for analysis, * p < 0.05 compared to nontreatment.
    Figure Legend Snippet: TSP‐2 inhibits angiogenesis in early passage ECs, and TSP‐5 may be protective against tubule disruption. (A, B) Angiogenesis was assessed by plating ECs overnight on a Matrigel‐based endothelial tubule formation assay and pretreating with or without TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in early passage ECs, but TSP‐5 inhibited tubule formation in late passage ECs. (C, D) To assess tubule disruption, EC tubules were allowed to form overnight and then treated for 24 h with TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in late passage ECs (D), TSP‐5 increased tubule formation in early passage ECs (C). In the postformation treatment groups, late passage ECs had more tubule disruption than early passage cells. Values are means ± SE. Student's t ‐test performed for analysis, * p < 0.05 compared to nontreatment.

    Techniques Used: Disruption, Tube Formation Assay



    Similar Products

    human aortic endothelial cells  (Cell Applications Inc)
    94
    Cell Applications Inc human aortic endothelial cells
    TSP‐2 inhibits angiogenesis in early passage ECs, and TSP‐5 may be protective against tubule disruption. (A, B) Angiogenesis was assessed by plating ECs overnight on a Matrigel‐based <t>endothelial</t> tubule formation assay and pretreating with or without TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in early passage ECs, but TSP‐5 inhibited tubule formation in late passage ECs. (C, D) To assess tubule disruption, EC tubules were allowed to form overnight and then treated for 24 h with TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in late passage ECs (D), TSP‐5 increased tubule formation in early passage ECs (C). In the postformation treatment groups, late passage ECs had more tubule disruption than early passage cells. Values are means ± SE. Student's t ‐test performed for analysis, * p < 0.05 compared to nontreatment.
    Human Aortic Endothelial Cells, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human aortic endothelial cells/product/Cell Applications Inc
    Average 94 stars, based on 1 article reviews
    human aortic endothelial cells - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    human cardiac fibroblasts hcfs  (Cell Applications Inc)
    95
    Cell Applications Inc human cardiac fibroblasts hcfs
    TSP‐2 inhibits angiogenesis in early passage ECs, and TSP‐5 may be protective against tubule disruption. (A, B) Angiogenesis was assessed by plating ECs overnight on a Matrigel‐based <t>endothelial</t> tubule formation assay and pretreating with or without TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in early passage ECs, but TSP‐5 inhibited tubule formation in late passage ECs. (C, D) To assess tubule disruption, EC tubules were allowed to form overnight and then treated for 24 h with TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in late passage ECs (D), TSP‐5 increased tubule formation in early passage ECs (C). In the postformation treatment groups, late passage ECs had more tubule disruption than early passage cells. Values are means ± SE. Student's t ‐test performed for analysis, * p < 0.05 compared to nontreatment.
    Human Cardiac Fibroblasts Hcfs, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human cardiac fibroblasts hcfs/product/Cell Applications Inc
    Average 95 stars, based on 1 article reviews
    human cardiac fibroblasts hcfs - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    133 inc  (Cell Applications Inc)
    95
    Cell Applications Inc 133 inc
    TSP‐2 inhibits angiogenesis in early passage ECs, and TSP‐5 may be protective against tubule disruption. (A, B) Angiogenesis was assessed by plating ECs overnight on a Matrigel‐based <t>endothelial</t> tubule formation assay and pretreating with or without TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in early passage ECs, but TSP‐5 inhibited tubule formation in late passage ECs. (C, D) To assess tubule disruption, EC tubules were allowed to form overnight and then treated for 24 h with TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in late passage ECs (D), TSP‐5 increased tubule formation in early passage ECs (C). In the postformation treatment groups, late passage ECs had more tubule disruption than early passage cells. Values are means ± SE. Student's t ‐test performed for analysis, * p < 0.05 compared to nontreatment.
    133 Inc, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/133 inc/product/Cell Applications Inc
    Average 95 stars, based on 1 article reviews
    133 inc - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    human epidermal melanocytes: hem  (Cell Applications Inc)
    94
    Cell Applications Inc human epidermal melanocytes: hem
    TSP‐2 inhibits angiogenesis in early passage ECs, and TSP‐5 may be protective against tubule disruption. (A, B) Angiogenesis was assessed by plating ECs overnight on a Matrigel‐based <t>endothelial</t> tubule formation assay and pretreating with or without TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in early passage ECs, but TSP‐5 inhibited tubule formation in late passage ECs. (C, D) To assess tubule disruption, EC tubules were allowed to form overnight and then treated for 24 h with TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in late passage ECs (D), TSP‐5 increased tubule formation in early passage ECs (C). In the postformation treatment groups, late passage ECs had more tubule disruption than early passage cells. Values are means ± SE. Student's t ‐test performed for analysis, * p < 0.05 compared to nontreatment.
    Human Epidermal Melanocytes: Hem, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human epidermal melanocytes: hem/product/Cell Applications Inc
    Average 94 stars, based on 1 article reviews
    human epidermal melanocytes: hem - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    donors  (Cell Applications Inc)
    94
    Cell Applications Inc donors
    TSP‐2 inhibits angiogenesis in early passage ECs, and TSP‐5 may be protective against tubule disruption. (A, B) Angiogenesis was assessed by plating ECs overnight on a Matrigel‐based <t>endothelial</t> tubule formation assay and pretreating with or without TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in early passage ECs, but TSP‐5 inhibited tubule formation in late passage ECs. (C, D) To assess tubule disruption, EC tubules were allowed to form overnight and then treated for 24 h with TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in late passage ECs (D), TSP‐5 increased tubule formation in early passage ECs (C). In the postformation treatment groups, late passage ECs had more tubule disruption than early passage cells. Values are means ± SE. Student's t ‐test performed for analysis, * p < 0.05 compared to nontreatment.
    Donors, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/donors/product/Cell Applications Inc
    Average 94 stars, based on 1 article reviews
    donors - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    human epidermal melanocytes  (Cell Applications Inc)
    94
    Cell Applications Inc human epidermal melanocytes
    TSP‐2 inhibits angiogenesis in early passage ECs, and TSP‐5 may be protective against tubule disruption. (A, B) Angiogenesis was assessed by plating ECs overnight on a Matrigel‐based <t>endothelial</t> tubule formation assay and pretreating with or without TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in early passage ECs, but TSP‐5 inhibited tubule formation in late passage ECs. (C, D) To assess tubule disruption, EC tubules were allowed to form overnight and then treated for 24 h with TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in late passage ECs (D), TSP‐5 increased tubule formation in early passage ECs (C). In the postformation treatment groups, late passage ECs had more tubule disruption than early passage cells. Values are means ± SE. Student's t ‐test performed for analysis, * p < 0.05 compared to nontreatment.
    Human Epidermal Melanocytes, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human epidermal melanocytes/product/Cell Applications Inc
    Average 94 stars, based on 1 article reviews
    human epidermal melanocytes - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    primary rat cortical astrocytes  (Cell Applications Inc)
    94
    Cell Applications Inc primary rat cortical astrocytes
    TSP‐2 inhibits angiogenesis in early passage ECs, and TSP‐5 may be protective against tubule disruption. (A, B) Angiogenesis was assessed by plating ECs overnight on a Matrigel‐based <t>endothelial</t> tubule formation assay and pretreating with or without TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in early passage ECs, but TSP‐5 inhibited tubule formation in late passage ECs. (C, D) To assess tubule disruption, EC tubules were allowed to form overnight and then treated for 24 h with TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in late passage ECs (D), TSP‐5 increased tubule formation in early passage ECs (C). In the postformation treatment groups, late passage ECs had more tubule disruption than early passage cells. Values are means ± SE. Student's t ‐test performed for analysis, * p < 0.05 compared to nontreatment.
    Primary Rat Cortical Astrocytes, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary rat cortical astrocytes/product/Cell Applications Inc
    Average 94 stars, based on 1 article reviews
    primary rat cortical astrocytes - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    22mb  (Cell Applications Inc)
    96
    Cell Applications Inc 22mb
    TSP‐2 inhibits angiogenesis in early passage ECs, and TSP‐5 may be protective against tubule disruption. (A, B) Angiogenesis was assessed by plating ECs overnight on a Matrigel‐based <t>endothelial</t> tubule formation assay and pretreating with or without TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in early passage ECs, but TSP‐5 inhibited tubule formation in late passage ECs. (C, D) To assess tubule disruption, EC tubules were allowed to form overnight and then treated for 24 h with TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in late passage ECs (D), TSP‐5 increased tubule formation in early passage ECs (C). In the postformation treatment groups, late passage ECs had more tubule disruption than early passage cells. Values are means ± SE. Student's t ‐test performed for analysis, * p < 0.05 compared to nontreatment.
    22mb, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/22mb/product/Cell Applications Inc
    Average 96 stars, based on 1 article reviews
    22mb - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    28fb  (Cell Applications Inc)
    96
    Cell Applications Inc 28fb
    TSP‐2 inhibits angiogenesis in early passage ECs, and TSP‐5 may be protective against tubule disruption. (A, B) Angiogenesis was assessed by plating ECs overnight on a Matrigel‐based <t>endothelial</t> tubule formation assay and pretreating with or without TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in early passage ECs, but TSP‐5 inhibited tubule formation in late passage ECs. (C, D) To assess tubule disruption, EC tubules were allowed to form overnight and then treated for 24 h with TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in late passage ECs (D), TSP‐5 increased tubule formation in early passage ECs (C). In the postformation treatment groups, late passage ECs had more tubule disruption than early passage cells. Values are means ± SE. Student's t ‐test performed for analysis, * p < 0.05 compared to nontreatment.
    28fb, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/28fb/product/Cell Applications Inc
    Average 96 stars, based on 1 article reviews
    28fb - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    human dermal fibroblasts: hdf  (Cell Applications Inc)
    96
    Cell Applications Inc human dermal fibroblasts: hdf
    TSP‐2 inhibits angiogenesis in early passage ECs, and TSP‐5 may be protective against tubule disruption. (A, B) Angiogenesis was assessed by plating ECs overnight on a Matrigel‐based <t>endothelial</t> tubule formation assay and pretreating with or without TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in early passage ECs, but TSP‐5 inhibited tubule formation in late passage ECs. (C, D) To assess tubule disruption, EC tubules were allowed to form overnight and then treated for 24 h with TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in late passage ECs (D), TSP‐5 increased tubule formation in early passage ECs (C). In the postformation treatment groups, late passage ECs had more tubule disruption than early passage cells. Values are means ± SE. Student's t ‐test performed for analysis, * p < 0.05 compared to nontreatment.
    Human Dermal Fibroblasts: Hdf, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human dermal fibroblasts: hdf/product/Cell Applications Inc
    Average 96 stars, based on 1 article reviews
    human dermal fibroblasts: hdf - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    TSP‐2 inhibits angiogenesis in early passage ECs, and TSP‐5 may be protective against tubule disruption. (A, B) Angiogenesis was assessed by plating ECs overnight on a Matrigel‐based endothelial tubule formation assay and pretreating with or without TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in early passage ECs, but TSP‐5 inhibited tubule formation in late passage ECs. (C, D) To assess tubule disruption, EC tubules were allowed to form overnight and then treated for 24 h with TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in late passage ECs (D), TSP‐5 increased tubule formation in early passage ECs (C). In the postformation treatment groups, late passage ECs had more tubule disruption than early passage cells. Values are means ± SE. Student's t ‐test performed for analysis, * p < 0.05 compared to nontreatment.

    Journal: FASEB BioAdvances

    Article Title: Age and Sex Impact the Role of Thrombospondin‐2 and Thrombospondin‐5 in Response to Hindlimb Ischemia

    doi: 10.1096/fba.2025-00258

    Figure Lengend Snippet: TSP‐2 inhibits angiogenesis in early passage ECs, and TSP‐5 may be protective against tubule disruption. (A, B) Angiogenesis was assessed by plating ECs overnight on a Matrigel‐based endothelial tubule formation assay and pretreating with or without TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in early passage ECs, but TSP‐5 inhibited tubule formation in late passage ECs. (C, D) To assess tubule disruption, EC tubules were allowed to form overnight and then treated for 24 h with TSP‐2 (5 μg/mL) or TSP‐5 (5 μg/mL). TSP‐2 inhibited tubule formation in late passage ECs (D), TSP‐5 increased tubule formation in early passage ECs (C). In the postformation treatment groups, late passage ECs had more tubule disruption than early passage cells. Values are means ± SE. Student's t ‐test performed for analysis, * p < 0.05 compared to nontreatment.

    Article Snippet: Human aortic endothelial cells (Cell Applications Inc., San Diego, CA, USA) were used in early passage (P3–P8) to represent young cells or late passage (P15–P18) to represent aged cells.

    Techniques: Disruption, Tube Formation Assay